Mark Milner, MD
Cardiovascular Disease · Bethesda, MDNPI 1093710360
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,450 of the $3,243 with a category attached, or 75.6%. Sun Pharmaceutical Industries Inc. accounts for 81.9% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2022 at $2,755 and has fallen 99.4% since, to $16 in 2025.
Across 25 payments — averaging $129.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$3K
- Novartis$234
- Shire North American Group Inc$108
- Quidel Corporation$76
- Medtronic$61
- GE HealthCare$42
- plus $66 from 2 others
What the payments were for
- Speaking & faculty fees$2,45076%
- Food & beverage$79324%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 12 | $2,656 |
| Novartis | 3 | $234 |
| Shire North American Group Inc | 1 | $108 |
| Quidel Corporation | 1 | $76 |
| Medtronic | 2 | $61 |
| GE HealthCare | 2 | $42 |
| Abbott | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,243 in reported general payments places this provider in the 60th percentile of 507 cardiovascular disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 216 | $297,775 |
| XareltoRivaroxaban | 29 | $41,422 |
| JardianceEmpagliflozin | 12 | $18,932 |
| Metoprolol Succinate | 319 | $7,392 |
| Ezetimibe | 108 | $4,949 |
| Atorvastatin Calcium | 320 | $4,769 |
| Ranolazine ErRanolazine | 18 | $3,058 |
| Rosuvastatin Calcium | 124 | $2,724 |
| Amlodipine Besylate | 243 | $2,202 |
| Losartan Potassium | 142 | $2,180 |
| Amiodarone Hcl | 53 | $1,759 |
| Atenolol | 130 | $1,604 |
| Flecainide Acetate | 17 | $1,445 |
| Potassium Chloride | 35 | $1,239 |
| Pravastatin Sodium | 34 | $1,207 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Bethesda
- Mark HaigneyBethesda$121K
- Robert GoldsteinBethesda$16K
- Navin KapurBaltimore$1.5M
- Michael BlahaBaltimore$609K
- Sanjay RajagopalanBaltimore$521K
- Allen TaylorN Bethesda$456K
- David GoorayLargo$333K
- Erin MichosBaltimore$257K
- Seth MartinBaltimore$166K
- Erika FellerBaltimore$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.